Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study
Clive H. Wilder‐Smith, Henrik Ahlbom(AstraZeneca (Sweden)), Kerstin Röhss(AstraZeneca (Sweden)), Patrik Bondarov(AstraZeneca (Sweden)), B. Hallerbäck(AstraZeneca (Sweden)), L.‐E. Svedberg(AstraZeneca (Sweden))
Cited by 29
Related Papers
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
|European Journal of Clinical Pharmacology|2000|140
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
|British Journal of Clinical Pharmacology|1998|124
Effect of Esomeprazole 40 mg vs Omeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease
|Digestive Diseases and Sciences|2002|93
Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intragastric Acidity in Healthy Subjects
|Scandinavian Journal of Gastroenterology|1993|58